The Mdm Network and Its Regulation of P53 Activities: a Rheostat of Cancer Risk

Overview

Journal Hum Mutat

Specialty Genetics

Date 2014 Feb 4

PMID 24488925

Citations 44

Authors

Christine M Eischen

Guillermina Lozano

Affiliations

Soon will be listed here.

Abstract

The potent transcriptional activity of p53 (Trp53, TP53) must be kept in check for normal cell growth and survival. Tumors, which drastically deviate from these parameters, have evolved multiple mechanisms to inactivate TP53, the most prevalent of which is the emergence of TP53 missense mutations, some of which have gain-of-function activities. Another important mechanism by which tumors bypass TP53 functions is via increased levels of two TP53 inhibitors, MDM2, and MDM4. Studies in humans and in mice reveal the complexity of TP53 regulation and the exquisite sensitivity of this pathway to small changes in regulation. Here, we summarize the factors that impinge on TP53 activity and thus cell death/arrest or tumor development.

Citing Articles

Raman active diyne-girder conformationally constrained p53 stapled peptides bind to MDM2 for visualisation without fluorophores.

Morgan D, McDougall L, Knuhtsen A, Buetow L, Steven C, Shepperson O RSC Chem Biol. 2025; 6(3):394-403.

PMID: 39830683 PMC: 11741006. DOI: 10.1039/d4cb00288a.

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.

Lu Y, Cho T, Mukherjee S, Suarez C, Gonzalez-Foutel N, Malik A Mol Syst Biol. 2024; 20(6):719-740.

PMID: 38580884 PMC: 11148184. DOI: 10.1038/s44320-024-00032-x.

Association of MDM2 Overexpression in Ameloblastomas with Amplification and BRAF Expression.

Tosios K, Kalogirou E, Koutlas I Int J Mol Sci. 2024; 25(4).

PMID: 38396916 PMC: 10889355. DOI: 10.3390/ijms25042238.

Genome-Wide Profiling of Transcriptome and DNA Methylome in Human Embryonic Stem Cells Exposed to Extractable Organic Matter from PM2.5.

Wang J, Liu T, Wang J, Chen T, Jiang Y Toxics. 2023; 11(10).

PMID: 37888691 PMC: 10611369. DOI: 10.3390/toxics11100840.

Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program.

Pant V, Sun C, Lozano G Cell Death Differ. 2023; 30(4):897-905.

PMID: 36755072 PMC: 10070629. DOI: 10.1038/s41418-023-01123-2.

References

Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R . Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 2004; 24(13):5835-43. PMC: 480894. DOI: 10.1128/MCB.24.13.5835-5843.2004. View

Midgley C, Lane D . p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 1997; 15(10):1179-89. DOI: 10.1038/sj.onc.1201459. View

Li Q, Lozano G . Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 2012; 19(1):34-41. PMC: 3537867. DOI: 10.1158/1078-0432.CCR-12-0053. View

Zindy F, Eischen C, Randle D, Kamijo T, Cleveland J, Sherr C . Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998; 12(15):2424-33. PMC: 317045. DOI: 10.1101/gad.12.15.2424. View

Tocque B, Wasylyk B . MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene. 1995; 11(11):2445-9. View

Zou M, Shi Y, Al-Sedairy S, Hussain S, Farid N . The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. Cancer. 1995; 76(2):314-8. DOI: 10.1002/1097-0142(19950715)76:2<314::aid-cncr2820760223>3.0.co;2-q. View

Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J . Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994; 145(3):702-14. PMC: 1890319. View

Cheng Q, Chen J . The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation. Cell Cycle. 2011; 10(7):1162-6. PMC: 3100889. DOI: 10.4161/cc.10.7.15249. View

Cummins J, Rago C, Kohli M, Kinzler K, Lengauer C, Vogelstein B . Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature. 2004; 428(6982):1 p following 486. DOI: 10.1038/nature02501. View

10.

Eischen C . Decreased Mdm2 levels after DNA damage: antibody masking or protein degradation?. Cell Cycle. 2011; 10(9):1347. DOI: 10.4161/cc.10.9.15437. View

11.

Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G . Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011; 108(29):11995-2000. PMC: 3141986. DOI: 10.1073/pnas.1102241108. View

12.

Post S, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson J . A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010; 18(3):220-30. PMC: 2944041. DOI: 10.1016/j.ccr.2010.07.010. View

13.

Xiong S, Pant V, Suh Y, Van Pelt C, Wang Y, Valentin-Vega Y . Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010; 70(18):7148-54. PMC: 2940952. DOI: 10.1158/0008-5472.CAN-10-1457. View

14.

Riemenschneider M, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus J . Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 2000; 59(24):6091-6. View

15.

Sanchez-Cespedes M, Reed A, Buta M, Wu L, Westra W, Herman J . Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene. 1999; 18(43):5843-9. DOI: 10.1038/sj.onc.1203003. View

16.

Linke K, Mace P, Smith C, Vaux D, Silke J, Day C . Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008; 15(5):841-8. DOI: 10.1038/sj.cdd.4402309. View

17.

Heinmoller E, Dietmaier W, Zirngibl H, Heinmoller P, Scaringe W, Jauch K . Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol. 2000; 157(1):83-92. PMC: 1850206. DOI: 10.1016/S0002-9440(10)64520-8. View

18.

Birch J, Blair V, Kelsey A, Evans D, Harris M, Tricker K . Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998; 17(9):1061-8. DOI: 10.1038/sj.onc.1202033. View

19.

Hustinx S, Leoni L, Yeo C, Brown P, Goggins M, Kern S . Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol. 2005; 18(7):959-63. DOI: 10.1038/modpathol.3800377. View

20.

Pant V, Xiong S, Jackson J, Post S, Abbas H, Quintas-Cardama A . The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev. 2013; 27(17):1857-67. PMC: 3778240. DOI: 10.1101/gad.227249.113. View